These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37840522)

  • 1. Pharmacokinetics and safety of injected ornidazole compared to its enantiomer levornidazole in healthy Chinese subjects.
    Liu Y; Zhang Y; Xue W; Wang J; Bai W; Wang T; Liu Y; Tang K; Qin J; Li K; Wang X
    Int J Clin Pharmacol Ther; 2023 Dec; 61(12):543-550. PubMed ID: 37840522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis.
    Guo B; He G; Wu X; Yu J; Cao G; Li Y; Fan Y; Chen Y; Shi Y; Zhang Y; Zhang J
    Clin Ther; 2017 Jul; 39(7):1336-1346. PubMed ID: 28619503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of levornidazole and its metabolites in human plasma and urine by ultra-performance liquid chromatography-mass spectrometry.
    Cao Y; Zhao M; Wu X; Guo B; Chen Y; Yu J; Cao G; Zhang J; Shi Y; Zhang Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():119-27. PubMed ID: 24953495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved pharmacokinetic profile of levornidazole following intravenous infusion of 750mg every 24h compared with 500mg every 12h in healthy Chinese volunteers.
    Cao Y; Wu X; Chen Y; Guo B; Yu J; Cao G; Zhang J; Shi Y; Zhang Y
    Int J Antimicrob Agents; 2016 Mar; 47(3):224-8. PubMed ID: 26920104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography-tandem mass spectrometry.
    He G; Guo B; Zhang J; Li Y; Wu X; Fan Y; Chen Y; Cao G; Yu J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1081-1082():87-100. PubMed ID: 29518721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal AnaerobicInfection.
    Wu H; Xie S; Yu J; Chen Y; Wu J; Guo B; Zhu Z; Zhou Y; Wang Z; Zhang J
    Clin Ther; 2018 Sep; 40(9):1548-1555. PubMed ID: 30146271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Anaerobic Pharmacokinetic/Pharmacodynamic Model to Simulate the Bactericidal Activity of Levornidazole Against Bacteroides fragilis.
    Hu J; Zhang J; Chen Y; Liang W; Wu S
    Clin Ther; 2017 Apr; 39(4):828-836. PubMed ID: 28363695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis.
    Cao Y; Li Y; Guo B; Zhang J; Wu X; Yu J; Cao G; Fan Y; Wu H
    Int J Antimicrob Agents; 2023 Apr; 61(4):106754. PubMed ID: 36773938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
    Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
    Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu H; Wang Z; Wang Y; Yu J; Fan Y; Li Y; Wang J; Cao G; Guo B; Chen Y; Liu X; Bian X; Wu J; Li H; Wu X; Zhang J
    Infect Dis Ther; 2021 Jun; 10(2):911-923. PubMed ID: 33826105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects.
    Sun F; Liu Y; Li T; Lin P; Jiang X; Li X; Wang C; Gao X; Ma Y; Fu Y; Cao Y
    BMC Pharmacol Toxicol; 2023 Feb; 24(1):7. PubMed ID: 36737825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of ornidazole and its main metabolites in human plasma by LC-MS/MS: application to a pharmacokinetic study.
    Du J; Ma Z; Zhang Y; Wang T; Chen X; Zhong D
    Bioanalysis; 2014 Sep; 6(18):2343-56. PubMed ID: 25384588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multicenter randomized controlled clinical study on levornidazole and sodium chloride injection in the treatment of pelvic anaerobic infections].
    Ma L; Zhang YZ; Zheng YL; Wang ZH; Xu YD; Kong LN
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):754-6. PubMed ID: 21176556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enantioselective determination of ornidazole in human plasma by liquid chromatography-tandem mass spectrometry on a Chiral-AGP column.
    Du J; Ma Z; Zhang Y; Wang T; Chen X; Zhong D
    J Pharm Biomed Anal; 2013 Dec; 86():182-8. PubMed ID: 24004635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
    Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
    Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic properties and safety profile of histamine dihydrochloride injection in Chinese healthy volunteers: a phase I, single-center, open-label, randomized study.
    Li J; Huang X; Wang Q; Jing S; Jiang H; Wei Z; Zang Y; Liu Y; Zhao L; Fang Y; Feng W
    Clin Ther; 2015 Oct; 37(10):2352-64. PubMed ID: 26276501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of chiral inversion and pharmacokinetics of laevo-ornidazole by high-performance liquid chromatography.
    Mu LL; Cheng ZN; Guo X; Luo X; Yu P
    J Clin Pharm Ther; 2013 Feb; 38(1):31-5. PubMed ID: 23167572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of two Voriconazole formulations after intravenous infusion in two doses in healthy Chinese subjects.
    Li X; Wang C; Shi P; Liu Y; Tao Y; Lin P; Li T; Hu H; Sun F; Liu S; Fu Y; Cao Y
    BMC Pharmacol Toxicol; 2023 Mar; 24(1):14. PubMed ID: 36869387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Potential Immunomodulatory Properties of Levornidazole Contribute to Improvement in Experimental Ulcerative Colitis.
    Wang XQ; Chen H; Gao YZ; Huang YX; Zhang RJ; Xie J; Li Y; Huang YQ; Gou LS; Yao RQ
    Curr Med Sci; 2021 Aug; 41(4):746-756. PubMed ID: 34403100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of ornidazole in patients with severe liver cirrhosis.
    Taburet AM; Delion F; Attali P; Thebault JJ; Singlas E
    Clin Pharmacol Ther; 1986 Sep; 40(3):359-64. PubMed ID: 3742940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.